Kezar Life Sciences Inc reports results for the quarter ended in June - Earnings Summary

Kezar Life Sciences

10/08/2023 21:20

* Kezar Life Sciences Inc  KZR.OQ  reported a quarterly
adjusted
loss of 34 cents​​ per share for the quarter ended in June. The
mean expectation of six analysts for the quarter was for a loss
of 32 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kezar Life Sciences Inc's reported EPS for the quarter was
a
loss of 34 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Kezar Life Sciences Inc shares had fallen by 18.0% this
quarter and lost 71.4% so far this year.
    * The company reported a quarterly loss of $24.31 million.
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 08:20 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.32          -0.34          Missed
 Mar. 31 2023      -0.29          -0.31          Missed
 Dec. 31 2022      -0.28          -0.25          Beat
 Sep. 30 2022      -0.27          -0.25          Beat